Could three FDA submissions turn bezuclastinib into a rare disease and oncology launch engine?
Cogent’s AdvSM NDA gives COGT a third bezuclastinib FDA submission, sharpening its KIT-driven disease franchise and late-2026 launch story.
MacroGenics exits GMP manufacturing operations as Bora expands U.S. biologics footprint
MacroGenics’ $122.5 million Bora sale boosts MGNX cash flexibility while shifting GMP manufacturing to a CDMO model.
Zoom targets buyer intelligence and AI revenue agents with Common Room acquisition
Zoom’s Common Room acquisition strengthens ZM’s AI revenue platform with buyer intelligence, GTM signals and revenue agents.
Could UniFirst’s Q3 results affect the Cintas acquisition spread for UNF stock?
UniFirst’s Q3 revenue rose 3.9%, but merger and ERP costs hit margins as UNF investors watch the Cintas deal and FTC review.
Why the Monaco bombing could expose Europe’s hidden security risks
Monaco bombing targeting Vadym Yermolaiev raises questions over elite security, Ukrainian wealth, sanctions, organized crime and Europe’s safe havens.
Why AVX stock investors should watch AVAX One’s Bantry Data Site LOI closely
AVAX One’s Alberta data centre LOI gives AVX a powered-site AI infrastructure catalyst, but the Bantry deal remains non-binding.
Why China’s ethnic unity law could deepen fears over minority assimilation
China’s ethnic unity law raises fears over minority assimilation, Mandarin education, overseas enforcement and Xi Jinping’s control agenda.
FactSet reports Q3 revenue growth as financial AI workflows gain traction
FactSet’s Q3 results show 7.1% organic ASV growth and rising AI adoption, sharpening the FDS stock story despite margin pressure.
Why Trump’s Supreme Court defeat on birthright citizenship may not end the fight
Trump’s birthright citizenship defeat blocks his executive order but leaves Congress, courts and immigration politics facing a deeper fight.
Is Nasdaq becoming the biggest winner of the 2026 IPO market comeback?
Nasdaq’s $129.3 billion first-half listings record strengthens NDAQ’s IPO market story as AI, aerospace, biotech and energy issuers return.